Evidence map›Paper›PMID 42042849›Full record

ArticlePharmacy (Basel, Switzerland)2026

Guidance for Use of Artificial Intelligence in Community Pharmacy Practice: Perspectives and Needs of Pharmacists in Ontario, Canada.

Zubin Austin, Paul Gregory

Abstract read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zubin AustinLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.ORCID 0000-0001-6055-2518
Paul GregoryLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.

Funding

Network to Improve Health Systems 240110
6 · The paper itself

Abstract

backgroundAs Artificial Intelligence (AI) proliferates in society, community pharmacists must make decisions as to how to responsibly adopt this technology in their practice. Currently, there are few regulatory requirements or tools to support pharmacists in ensuring safe and ethical integration of AI in their work.

methodsAn exploratory qualitative study of community pharmacists in Ontario, Canada was undertaken to examine their needs for guidance, regulation, and support in adopting AI in their practice.

resultsSemi-structured interviews with 24 community pharmacists were undertaken to the point of thematic saturation. Constant-comparative analysis highlighted three key themes: (a) currently, AI is being used in unstandardized and unregulated ways; (b) pharmacists desire guidance or regulation focused on patient safety considerations; and (c) in the absence of regulation, ad hoc informal decision making is occurring.

conclusionsWith or without formal regulation, AI is being adopted in pharmacy practice. Current reliance on informal network support without clear regulatory guidance raises concerns for pharmacists regarding patient safety and their work as professionals.

Indexed as

artificial intelligencecommunity pharmacypharmacy practice

Identifiers

PMID42042849
PMCPMC13118915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.